Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7956805 | 0.97 | L3MBTL1 (0.60) | L3MBTL1CHRNA1CHRNA7CHRNA3CHRNB2 | |
| SCHEMBL17479542 | 0.95 | L3MBTL1 (0.63) | L3MBTL1CHRNA1CHRNA7CHRNA3CHRNB2 | |
| SCHEMBL7961750 | 0.84 | CHRNA7 (0.56) | CHRNA1CHRNA7CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL11200681 | 0.83 | L3MBTL1 (0.76) | L3MBTL1HRH3ACACB | |
| SCHEMBL7503846 | 0.82 | CHRNA7 (0.59) | CHRNA1CHRNA7CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL13853395 | 0.82 | L3MBTL1 (0.53) | L3MBTL1HRH3ACACB | |
| SCHEMBL18291700 | 0.82 | L3MBTL1 (0.53) | L3MBTL1CHRNA1CHRNA7CHRNA3CHRNB2 | |
| SCHEMBL4747810 | 0.82 | L3MBTL1 (0.53) | L3MBTL1HRH3ACACB | |
| SCHEMBL20255475 | 0.82 | L3MBTL1 (0.53) | L3MBTL1HRH3ACACB | |
| SCHEMBL7956397 | 0.81 | CHRNA7 (0.56) | CHRNA1CHRNA7CHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016016131-A1 | PESTICIDALLY ACTIVE CYCLIC ENAMINONES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016131-A1 | PESTICIDALLY ACTIVE CYCLIC ENAMINONES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2475657-B1 | 5-ALKINYLTHIEN-2-YLCARBOXYLIC ACIDS AS INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-2475657-B1 | 5-ALKINYLTHIEN-2-YLCARBOXYLIC ACIDS AS INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-2475657-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| CN-102471327-A | Inhibitors of flaviviridae viruses | GILEAD SCIENCES INC | 2012-05-23 | — | — | CN | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2011011303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2011011303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-6303638-B1 | FOR THERAPY OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, INCLUDING ALZHEIMER'S DISEASE, TOURETTE'S SYNDROME, COGNITIVE DYSFUNCTION E.G., DISORDERS OF ATTENTION, FOCUS AND CONCENTRATION, SUCH AS ATTENTION DEFICIT DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | L3MBTL1 3336/4885CHRNA1 4682/4885CHRNA7 4785/4885 |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | L3MBTL1 3336/4885CHRNA1 4682/4885CHRNA7 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.